These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33669671)

  • 1. Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells.
    Andreidesz K; Koszegi B; Kovacs D; Bagone Vantus V; Gallyas F; Kovacs K
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
    Pierce A; McGowan PM; Cotter M; Mullooly M; O'Donovan N; Rani S; O'Driscoll L; Crown J; Duffy MJ
    Cancer Biol Ther; 2013 Jun; 14(6):537-45. PubMed ID: 23760496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy.
    Sriramulu S; Thoidingjam S; Siddiqui F; Brown SL; Movsas B; Walker E; Nyati S
    Biomolecules; 2024 May; 14(6):. PubMed ID: 38927028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
    Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
    Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression.
    Li Y; Wang Y; Zhang W; Wang X; Chen L; Wang S
    Sci Rep; 2021 Feb; 11(1):4774. PubMed ID: 33637776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
    Ren H; Bakas NA; Vamos M; Chaikuad A; Limpert AS; Wimer CD; Brun SN; Lambert LJ; Tautz L; Celeridad M; Sheffler DJ; Knapp S; Shaw RJ; Cosford NDP
    J Med Chem; 2020 Dec; 63(23):14609-14625. PubMed ID: 33200929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
    Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib.
    Chen T; Liu C; Lu H; Yin M; Shao C; Hu X; Wu J; Wang Y
    Tumour Biol; 2017 Oct; 39(10):1010428317713390. PubMed ID: 29064327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple‑negative breast cancer cells.
    Zhao H; Yang Q; Hu Y; Zhang J
    Oncol Rep; 2018 Dec; 40(6):3223-3234. PubMed ID: 30272286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
    Wang J; He G; Li H; Ge Y; Wang S; Xu Y; Zhu Q
    Eur J Med Chem; 2021 Mar; 213():113054. PubMed ID: 33309164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer.
    Corrales-Sánchez V; Noblejas-López MDM; Nieto-Jiménez C; Pérez-Peña J; Montero JC; Burgos M; Galán-Moya EM; Pandiella A; Ocaña A
    J Cell Mol Med; 2020 Mar; 24(5):3117-3127. PubMed ID: 32032474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
    Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.
    McDonald ES; Mankoff J; Makvandi M; Chu W; Chu Y; Mach RH; Zeng C
    Biochem Biophys Res Commun; 2017 May; 486(3):788-795. PubMed ID: 28347815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells.
    Zeng X; Jiang S; Ruan S; Guo Z; Guo J; Liu M; Ye C; Dong J
    Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34080025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.